$AUPH News
Last published 1w ago
- 1w agoAUPHAurinia Pharmaceuticals Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1w agoAUPHAurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2026 and Provides Update on Recent Business ProgressBusiness WireAurinia Pharmaceuticals Inc. (NASDAQ:AUPH) today announced financial results for the three and nine months ended September 30, 2026 and provided an update on recent business progress. Financial Results Total
- 2mo agoAUPHAurinia Settles Patent Litigation with TevaBusiness WireAurinia Pharmaceuticals Inc. (NASDAQ:AUPH) today announced that it and its subsidiary, Aurinia Pharma U.S., Inc., (collectively, "Aurinia") have entered into a settlement agreement with Teva Pharmaceuticals
- 3mo agoAUPHAurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business ProgressBusiness WireAurinia Pharmaceuticals Inc. (NASDAQ:AUPH) today announced financial results for the three and six months ended June 30, 2026 and provided an update on recent business progress. Financial Results Total Revenue:
- 4mo agoAUPHAurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus NephritisBusiness Wire— Multitarget Approach Has Potential to Further Improve Outcomes in This Disease Characterized by Continued Unmet Need — Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) today announced the initiation of PRESERVE, a Phase
- 5mo agoAUPHLUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or DeathBusiness Wire— New Analysis of the AURORA 1 Phase 3 Study Presented at EULAR 2026 Congress — Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) today announced that a new analysis of the AURORA 1 Phase 3 study of LUPKYNIS® in the
- 6mo agoAUPHAurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business ProgressBusiness WireAurinia Pharmaceuticals Inc. (NASDAQ:AUPH) today announced financial results for the three months ended March 31, 2026 and provided an update on recent business progress. Financial Results Total Revenue: For the
- 7mo agoAUPHKZRAurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value RightBusiness WireAurinia Pharmaceuticals Inc. (NASDAQ:AUPH), a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs, announced today it has entered into a
- 7mo agoAUPHMKT Capital Applauds Aurinia Pharmaceuticals' Management TransitionBusiness WireBelieves the Board's Decision to Remove CEO Peter Greenleaf and Install Kevin Tang as CEO Validates Multi-Year Shareholder Campaign Commends New Leadership's Commitment to Shareholder Alignment Through Zero CEO
- 7mo agoAUPHAurinia Announces Management TransitionBusiness WireAurinia Pharmaceuticals Inc. (NASDAQ:AUPH) announced today that Kevin Tang, Aurinia's Chair of the Board, will succeed Peter Greenleaf as Chief Executive Officer. Peter will continue as a consultant to facilitate the
- 8mo agoAUPHAurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provides Update on Recent Business ProgressBusiness WireFull Year 2025 LUPKYNIS Sales Grew 25% Announces LUPKYNIS Sales Guidance for 2026 of $305 Million to $315 Million Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) today announced financial results for the three and twelve
- 8mo agoAUPHAurinia Pharmaceuticals to Report Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provide Update on Recent Business Progress on February 26, 2026Business WireAurinia Pharmaceuticals Inc. (NASDAQ:AUPH) today announced that it will report financial results for the three and twelve months ended December 31, 2025, and provide an update on recent business progress on February 26,
- 1y agoAUPHAurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2025 and Provides Update on Recent Business ProgressBusiness WireThird Quarter 2025 LUPKYNIS Sales Grew 27% LUPKYNIS Sales Guidance for 2025 Raised to $265 Million to $270 Million Aritinercept Advances Toward Clinical Studies in Two Autoimmune Diseases Aurinia Pharmaceuticals Inc.
- 1y agoAUPHAurinia Pharmaceuticals to Report Financial Results for the Three and Nine Months Ended September 30, 2025 and Provide Update on Recent Business Progress on November 4, 2025Business WireAurinia Pharmaceuticals Inc. (NASDAQ:AUPH) today announced that it will report financial results for the three and nine months ended September 30, 2025, and provide an update on recent business progress on November 4,
- 1y agoAUPHAurinia Announces Upcoming Presentations of New Data on LUPKYNIS® at American College of Rheumatology Convergence and American Society of Nephrology Kidney Week 2025Business WireAurinia Pharmaceuticals Inc. (NASDAQ:AUPH) today announced that five posters will be presented in collaboration with independent investigators highlighting new data on LUPKYNIS® (voclosporin) at the American
- 1y agoAUPHApproval of Lupkynis, Nda #213716 (Labeling)FDA Approved DrugsApproval Date: 10/08/2025; Drug Name: Lupkynis, Nda #213716; Active Ingredients: VOCLOSPORIN; Company: Aurinia; Submission Status: Approval; Submission Classification: Labeling; Application Number: 213716
- 1y agoAUPHAurinia Pharmaceuticals Inc. (AUPH) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoAUPHAurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2025Business WireAurinia Pharmaceuticals Inc. (NASDAQ:AUPH) today announced financial results for the three and six months ended June 30, 2025. Financial Results Total Revenue: For the three and six months ended June 30, 2025,
- 1y agoAUPHAurinia Pharmaceuticals to Release Second Quarter 2025 Financial and Operational Results on July 31, 2025Business WireAurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company) today announced that it will release second quarter 2025 financial and operational results before markets open on July 31, 2025. Aurinia's management
- 1y agoAUPHAurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200)Business WireSingle Doses of Aritinercept Led to Robust and Long-Lasting Reductions in Immunoglobulins Pharmacodynamic Effects Supportive of Once-Monthly Dosing Plan to Initiate Clinical Studies in at Least Two Autoimmune
- 1y agoAUPHAurinia Pharmaceuticals to Host Conference Call to Discuss AUR200 Phase 1 Study Results on June 30, 2025Business WireAurinia Pharmaceuticals Inc. (NASDAQ:AUPH) today announced that it will host a webcast and conference call on June 30, 2025, at 8:30 a.m. ET to discuss AUR200 Phase 1 study results. The link to the webcast is available
- 1y agoAUPHNew AURORA 1 Analysis: LUPKYNIS-Based Triple Immunosuppressive Therapy Yields Deep Proteinuria Reduction in Lupus NephritisBusiness WireLUPKYNIS Data Presented at LUPUS 2025, the 16th International Congress on SLE, May 21-24 Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), today announced that a post-hoc analysis of the 52-week,
- 1y agoAUPHAurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025Business WireAurinia Pharmaceuticals Inc. (NASDAQ:AUPH) today announced financial results for the three months ended March 31, 2025. First Quarter 2025 Financial Results Total Revenue: For the three months ended March 31, 2025,
- 1y agoAUPHAurinia Pharmaceuticals to Release First Quarter 2025 Financial and Operational Results on May 12, 2025Business WireAurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company) today announced that it will release first quarter 2025 financial and operational results before markets open on May 12, 2025. Aurinia's management
- 1y agoAUPHGlass Lewis Recommends That Aurinia Shareholders Vote "FOR" All Proposals at 2025 Annual General MeetingBusiness WireAurinia Pharmaceuticals Inc. ("Aurinia" or the "Company") (NASDAQ:AUPH) today announced that leading independent proxy advisor Glass, Lewis & Co. LLC ("Glass Lewis") has recommended that Aurinia shareholders vote
- 1y agoAUPHISS Recommends That Aurinia Shareholders Vote "FOR" All Proposals at 2025 Annual General MeetingBusiness WireAurinia Pharmaceuticals Inc. ("Aurinia" or the "Company") (NASDAQ:AUPH) today announced that leading independent proxy advisor Institutional Shareholder Services ("ISS") has recommended that Aurinia shareholders vote
- 1y agoAUPHConcerned Shareholders of Aurinia Pharmaceuticals Announce Their Intention to Withhold Support for CEO Peter Greenleaf at 2025 Annual MeetingBusiness WireAre Encouraged by the Positive Governance and Operational Measures Implemented Under New Board Chair Kevin Tang Believe Shareholders Would Be Better Served by the Removal of CEO Peter Greenleaf, Who Has a Track Record
- 1y agoAUPHAurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2024 and Provides Update on Recent Corporate ProgressBusiness WireAurinia Pharmaceuticals Inc. (NASDAQ:AUPH) today announced financial results for the three and twelve months ended December 31, 2024 and provided an update on recent corporate progress. Fourth Quarter 2024 Financial
- 1y agoAUPHAurinia Pharmaceuticals to Release 2024 Fourth Quarter and Full Year Financial and Operational Results on February 27, 2025Business WireAurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company) today announced that it will release 2024 fourth quarter and full year financial and operational results before markets open on February 27,
- 1y agoAUPHAurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus NephritisBusiness WireNew Guidelines Presented at ACR Convergence 2024 Recommend First-Line Therapy with LUPKYNIS® (voclosporin) as Part of a Triple Immunosuppressive LN Treatment Regimen Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)
- 1y agoAUPHAurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® in Managing LN at American College of Rheumatology Convergence 2024Business WireAurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), announced today the acceptance of four poster presentations at the annual American College of Rheumatology Convergence (ACR) 2024 taking place in
- 1y agoAUPHAurinia to Participate in Jefferies London Healthcare ConferenceBusiness WireAurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company) today announced that the Company's management team will attend the Jefferies Healthcare Conference in London, November 19-21, 2024. Aurinia
- 2y agoAUPHAurinia Pharmaceuticals, Inc. (AUPH) Q3 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoAUPHAurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of GrowthBusiness WireAurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company) today announced that it has appointed Craig Johnson to its Board of Directors (the Board) to support its next phase of growth. Mr. Johnson has more
- 2y agoAUPHAurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS® Growth and AUR200 DevelopmentBusiness WireAchieved $67.8 million in total net revenue and $55.5 million in net product revenue for the third quarter of 2024, representing year-over-year growth of 24% and 36%, respectively Generated $17.0 million in cash flow
- 2y agoAUPHAurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 7, 2024Business WireAurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the third quarter of 2024 before markets open on November 7,
- 2y agoAUPHAPLSCMPITPTX+5Axonis Therapeutics Announces $115 Million Series A FinancingPR NewswireAxonis Therapeutics, a biotechnology company focused on the development of novel neuromedicines, announced today the successful completion of an...
- 2y agoAUPHAurinia Presents New Data Highlighting Real-World Utilization and Value of LUPKYNIS® in Treating Lupus Nephritis at American Society of Nephrology Kidney Week 2024Business WireAurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), announced today the acceptance of six abstracts, including five poster presentations, at the American Society of Nephrology (ASN) Kidney Week 2024
- 2y agoAUPHAurinia Announces Japan Approval of LUPKYNIS® (Voclosporin) to Treat Lupus NephritisBusiness WireAurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company) today announced that the Japanese Ministry of Health, Labour, and Welfare has approved voclosporin, a second-generation calcineurin inhibitor, in
- 2y agoAUPHAurinia to Participate in 2024 Cantor Fitzgerald Global Healthcare ConferenceBusiness WireAurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company) today announced that the Company's management team will attend the 2024 Cantor Fitzgerald Global Healthcare Conference in New York City, September
- 2y agoAUPHAurinia Announces Board RestructuringBusiness WirePeter Greenleaf, President and Chief Executive Officer of Aurinia, remains a Director Kevin Tang, President of Tang Capital Management, LLC, appointed as a Director The Board has accepted the conditional
- 2y agoAUPHAurinia Announces First Participant Dosed in AUR200 Single Ascending Dose TrialBusiness WireAurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company) announced today that the first participant has been dosed in a Phase 1a single ascending dose (SAD) study of AUR200, a differentiated, potential
- 2y agoAUPHAurinia to Participate in H.C. Wainwright 26th Annual Global Investment ConferenceBusiness WireAurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company) today announced that the Company's management team will attend the H.C. Wainwright 26th Annual Global Investment Conference in New York City, September
- 2y agoAUPHAurinia Pharmaceuticals Shareholder Calls for CEO Peter Greenleaf, Dr. Brinda Balakrishnan, and Dr. Robert Foster to Resign from the BoardBusiness WireHighlights Damning Annual General Meeting Results, Which Show That Four of the Company's Nine Directors Failed to Receive a Majority of the Votes Calls on the Company to Appoint Two Shareholder Representatives to
- 2y agoAUPHAurinia Pharmaceuticals, Inc. (AUPH) Q2 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoAKROAPLSAUPHHRMY+5venBio Raises $528 Million Venture Capital Fund Focused on Life Science CompaniesBusiness Wire- venBio promotes Yvonne Yamanaka, Ph.D. to Partner venBio today announced the closing of venBio Global Strategic Fund V ("venBio Fund V"), its fifth life sciences venture capital fund, exceeding its target and
- 2y agoAUPHAurinia Pharmaceuticals Reports Second Quarter and Six Months 2024 Financial and Operational ResultsBusiness WireCompany achieved $57.2 million in total net revenue and $55.0 million in net product revenue for the second quarter of 2024, representing year-over-year growth of approximately 38% and 34% respectively Company
- 2y agoAUPHAurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 1, 2024Business WireAurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the second quarter of 2024 on Thursday, August 1, 2024, before markets open.
- 2y agoAUPHILJIN SNT Co., Ltd. Calls on Board of Aurinia Pharmaceuticals to Honor Shareholders' Voices Expressed at the AGMBusiness WireOne of Company's Largest and Longest-Standing Shareholders Urges Board to Accept Director Resignations Announces Intentions to Maintain Vigilance and Continue Actions to Restore Shareholder Value ILJIN SNT Co., Ltd.
- 2y agoAUPHAurinia to Participate in Upcoming Investor Healthcare ConferencesBusiness WireAurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company) today announced that the Company's management team will participate in one-on-one meetings with investors at the Leerink Partners Therapeutics Forum: